William Sharfman is an Oncology physician affiliated with Bloomberg. OpenAlex indexes 131 publications with 30,226 citations (h-index 46); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10755 Falls Rd
Lutherville, MD 210934515
Telephone
410-583-2970Registry record last updated 18 Feb 2013.
Clinical trials
- HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Sponsor: Clinigen, Inc.
- Melanoma Biomarker Study
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- Merck Sharp & Dohme LLCProgram year20239 payments$10,687openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.7%PD-1 inhibitor51.9%Nivolumab61%Pembrolizumab39%Part B, office-administered≥29 patientsCD38-directed Cytolytic Antibody23.3%Daratumumab100%Part B, office-administered≥21 patients+ 6 more classes in this area
Metabolism & gastrointestinal
7%Other antiemetics5.4%Fosaprepitant100%Part B, office-administered≥16 patientsSerotonin-3 Receptor Antagonist1.6%Ondansetron hydrochloride100%Part B, office-administered≥43 patients+ 2 more classes in this area
Sensory organs
1.1%Corticosteroid1.1%Dexamethasone sodium phosphate97%Hydrocortisone2%Dexamethasone1%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
Journal of Clinical Oncology
2024 - Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology
2023 - Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Arturo Casadevall, MD
Bloomberg
Elizabeth Jaffee, MD
Bloomberg
Daniel Laheru, MD
Bloomberg
Cynthia Sears, MD
Bloomberg
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”